Search research articles
Contact Us
Filters
Showing results (141-150 of 165) with videos related to
Page
of 17
Sort By:
Pathogens & Immunity
|
May 20, 2026
Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19
Evelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 study
Evelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Elife
|
October 14, 2022
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
Zicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 9, 2020
Proinflammatory IgG Fc structures in patients with severe COVID-19
Saborni Chakraborty, Joseph Gonzalez, Karlie Edwards, et al.
Nature Immunology
|
November 10, 2020
Proinflammatory IgG Fc structures in patients with severe COVID-19
Saborni Chakraborty, Joseph Gonzalez, Karlie Edwards, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
August 11, 2017
Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
Stephen Salloway, Jose E Gamez, Upinder Singh, et al.
JAMA Neurology
|
January 27, 2015
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density
Craig Curtis, Jose E Gamez, Upinder Singh, et al.
JAMA Internal Medicine
|
June 7, 2024
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial
Linda N Geng, Hector Bonilla, Haley Hedlin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
JAMA Network Open
|
October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 165) with videos related to
Sort By:
Page
of 17
Pathogens & Immunity
|
May 20, 2026
Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19
Evelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 study
Evelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Elife
|
October 14, 2022
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
Zicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 9, 2020
Proinflammatory IgG Fc structures in patients with severe COVID-19
Saborni Chakraborty, Joseph Gonzalez, Karlie Edwards, et al.
Nature Immunology
|
November 10, 2020
Proinflammatory IgG Fc structures in patients with severe COVID-19
Saborni Chakraborty, Joseph Gonzalez, Karlie Edwards, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
August 11, 2017
Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
Stephen Salloway, Jose E Gamez, Upinder Singh, et al.
JAMA Neurology
|
January 27, 2015
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density
Craig Curtis, Jose E Gamez, Upinder Singh, et al.
JAMA Internal Medicine
|
June 7, 2024
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial
Linda N Geng, Hector Bonilla, Haley Hedlin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
JAMA Network Open
|
October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Page
of 17